37554-70-4

Usage

Uses

Used in Pharmaceutical Industry:
2-chloro-5-fluoro-4-methoxypyrimidine is used as a key intermediate in the synthesis of pharmaceuticals for its ability to undergo nucleophilic substitution and cross-coupling reactions, leading to the development of new drug candidates with potentially beneficial properties.
Used in Agrochemical Industry:
In the agrochemical sector, 2-chloro-5-fluoro-4-methoxypyrimidine serves as a crucial building block for the creation of novel agrochemicals, contributing to the advancement of crop protection and pest management solutions.
Used in Organic Synthesis:
2-chloro-5-fluoro-4-methoxypyrimidine is utilized as a valuable reagent in organic synthesis due to its diverse reactivity and functional groups, enabling the production of a wide range of chemical derivatives for research and industrial applications.

Upstream product

• 67-56-1 methanol 
• 2927-71-1 2,4-dichloro-5-fluoropyrimidine 
• 124-41-4 sodium methylate 

Downstream Products

• 1454303-02-6 5-(5-fluoro-4-methoxy-pyrimidin-2-yl)-2-phenoxymethyl-6,7-dihydro-5H-oxazolo [5,4-c]pyridin-4-one 
• 1312535-38-8 5-fluoro-4-methoxy-N-[3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrimidin-2-amine 
• 1401349-58-3 N-tert-butyl-5-(3-(4-cyclopropyl-5-fluoropyrimidin-2-yl)-1-tosyl-1H-indol-5-yl)-1,3,4-oxadiazol-2-amine 
• 1401349-57-2 N-tert-butyl-5-(3-(5-fluoro-4-methoxypyrimidin-2-yl)-1-tosyl-1H-indol-5-yl)-1,3,4-oxadiazol-2-amine 
• 1382782-95-7 5-(5-fluoro-4-methoxy-pyrimidin-2-yl)-2-phenoxymethyl-6,7-dihydro-5H-pyrazolo[1,5-a]pyrazin-4-one 
• 1365748-94-2 (5-fluoro-4-methoxypyrimidin-2-yl)phenylamine 

Relevant academic research and scientific papers

Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety

Herein we describe structure-activity relationship (SAR) and metabolite identification (Met-ID) studies that provided insight into the origin of time-dependent inhibition (TDI) of cytochrome P450 3A4 (CYP3A4) by compound 1. Collectively, these efforts revealed that bioactivation of the fluoropyrimidine moiety of 1 led to reactive metabolite formation via oxidative defluorination and was responsible for the observed TDI. We discovered that substitution at both the 4- and 6-positions of the 5-fluoropyrimidine of 1 was necessary to ameliorate this TDI as exemplified by compound 19.

Structure-Based Design of an Iminoheterocyclic β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central Aβ in Nonhuman Primates

We describe successful efforts to optimize the in vivo profile and address off-target liabilities of a series of BACE1 inhibitors represented by 6 that embodies the recently validated fused pyrrolidine iminopyrimidinone scaffold. Employing structure-based design, truncation of the cyanophenyl group of 6 that binds in the S3 pocket of BACE1 followed by modification of the thienyl group in S1 was pursued. Optimization of the pyrimidine substituent that binds in the S2′-S2″ pocket of BACE1 remediated time-dependent CYP3A4 inhibition of earlier analogues in this series and imparted high BACE1 affinity. These efforts resulted in the discovery of difluorophenyl analogue 9 (MBi-4), which robustly lowered CSF and cortex Aβ40 in both rats and cynomolgus monkeys following a single oral dose. Compound 9 represents a unique molecular shape among BACE inhibitors reported to potently lower central Aβ in nonrodent preclinical species.

Facile and regioselective synthesis of novel 2,4-disubstituted-5- fluoropyrimidines as potential kinase inhibitors

2,4-Disubstituted-5-fluoropyrimidine is a biologically active molecular core seen in various anticancer agents such as 5-fluorouracil (5-FU). As part of a programme aimed at discovering kinase inhibitors, routes to two series of novel compounds (5-fluorop

AZOLE COMPOUNDS AS PIM INHIBITORS

The invention relates to bicyclic compounds of formulas I and Ia, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further em

IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS

New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

Imidazopyridine derivatives as JAK inhibitors

New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

PYRAZOLE DERIVATIVES AS JAK INHIBITORS

New pyrazole derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

Pyrazole derivatives as jak inhibitors

New pyrazole derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

Chemoselectivity and Regoselectivity in Reactions of Pyrimidines

Selective nucleophilic substitution and hydrogenolysis reactions in pyrimidines are discussed.Stepwise oxidation reactions of pyrimidine sulfides and HPLC studies of these are reported.